文献速递心境障碍

氯胺酮快速减轻重性抑郁自杀意念:咪达唑仑对照随机临床试验

Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial.
PubMed 文献 · Am J Psychiatry · 2017-12-05

该随机临床试验纳入80例当前重性抑郁障碍且SSI≥4的成人,比较辅助亚麻醉剂量静脉氯胺酮与咪达唑仑对自杀意念的急性效应。结果显示氯胺酮组第1天SSI评分下降比咪达唑仑组多4.96分,应答者比例55%对30%,且部分独立于抗抑郁效应。

要点

  • 氯胺酮组第1天SSI评分降幅比咪达唑仑组大4.96分(95%CI 2.33-7.59)。
  • 第1天应答率(SSI降幅≥50%)氯胺酮组55%,咪达唑仑组30%。
  • 氯胺酮对SSI的效应有33.6%由抑郁症状改善中介。

核心结论

  • 在重性抑郁障碍伴临床显著自杀意念的成人中,辅助亚麻醉剂量静脉氯胺酮在24小时内减轻自杀意念的效应大于咪达唑仑。

研究设计与样本

  • 随机临床试验纳入80例当前重性抑郁障碍且SSI评分≥4的成人,54%(43例)正在服用抗抑郁药。
  • 受试者随机接受氯胺酮或咪达唑仑输注,主要结局为输注后24小时(第1天)SSI评分。

主要发现

  • 第1天SSI评分下降氯胺酮组比咪达唑仑组多4.96分(95%CI=2.33, 7.59;Cohen's d=0.75)。
  • 第1天应答者(SSI评分下降≥50%)比例氯胺酮组为55%,咪达唑仑组为30%(OR=2.85,95%CI=1.14, 7.15;NNT=4.0)。
  • 第1天POMS抑郁分量表改善氯胺酮组更大(估计值=7.65,95%CI=1.36, 13.94),该效应中介了氯胺酮对SSI评分的33.6%效应。
  • 不良反应短暂,在非对照随访中加用优化的标准药物治疗后临床改善维持至6周。

关键数值与推荐

  • 自杀意念应答定义为SSI评分下降≥50%。
  • 主要结局为输注后24小时SSI评分。

临床怎么用

  • 对于重性抑郁障碍伴临床显著自杀意念的成人,可考虑辅助亚麻醉剂量静脉氯胺酮以在24小时内快速减轻自杀意念。
  • 氯胺酮对自杀意念的效应部分独立于抗抑郁效应,临床评估需同时关注自杀意念与抑郁症状。

局限性

  • 随访期为非对照设计,维持效应至6周的结论需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Pharmacotherapy to rapidly relieve suicidal ideation in depression may reduce suicide risk. Rapid reduction in suicidal thoughts after ketamine treatment has mostly been studied in patients with low levels of suicidal ideation. The authors tested the acute effect of adjunctive subanesthetic intravenous ketamine on clinically significant suicidal ideation in patients with major depressive disorder. METHOD: In a randomized clinical trial, adults (N=80) with current major depressive disorder and a score ≥4 on the Scale for Suicidal Ideation (SSI), of whom 54% (N=43) were taking antidepressant medication, were randomly assigned to receive ketamine or midazolam infusion. The primary outcome measure was SSI score 24 hours after infusion (at day 1). RESULTS: The reduction in SSI score at day 1 was 4.96 points greater for the ketamine group compared with the midazolam group (95% CI=2.33, 7.59; Cohen's d=0.75). The proportion of responders (defined as having a reduction ≥50% in SSI score) at day 1 was 55% for the ketamine group and 30% for the midazolam group (odds ratio=2.85, 95% CI=1.14, 7.15; number needed to treat=4.0). Improvement in the Profile of Mood States depression subscale was greater at day 1 for the ketamine group compared with the midazolam group (estimate=7.65, 95% CI=1.36, 13.94), and this effect mediated 33.6% of ketamine's effect on SSI score. Side effects were short-lived, and clinical improvement was maintained for up to 6 weeks with additional optimized standard pharmacotherapy in an uncontrolled follow-up. CONCLUSIONS: Adjunctive ketamine demonstrated a greater reduction in clinically significant suicidal ideation in depressed patients within 24 hours compared with midazolam, partially independently of antidepressant effect.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Grunebaum MF, Galfalvy HC, Choo TH, et al. Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial. Am J Psychiatry. 2017. PMID: 29202655. doi:10.1176/appi.ajp.2017.17060647

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。